Research Paper Volume 14, Issue 24 pp 10171—10216

Figure 6. TMEscore was a prognostic and immunotherapeutic biomarker in Gide, Kim and TCGA GIAC cohort. (A–C) The survival time (OS and PFS) and response rate of patients with high/low TMEscore for 41 patients treated with PD1+CTLA4 inhibitor in Gide cohort. (D) The TMEscore of patients with different response status for patients treated with PD1+CTLA4 inhibitor. (E) The ROC curve of TMEscore predicting immunotherapeutic response for patients treated with PD1+CTLA4 inhibitor. (F–H) The survival time (OS and PFS) and response rate of patients with high/low TMEscore for 32 patients treated with PD1 inhibitor in Gide cohort. (I) The TMEscore of patients with different response status for patients treated with PD1 inhibitor. (J) The ROC curve of TMEscore predicting immunotherapeutic response for patients treated with PD1 inhibitor. (K) The response rate of patients with high/low TMEscore for 45 gastric cancer patients treated with PD1 inhibitor in Kim cohort. (L) The TMEscore of patients with different response status for patients treated with PD1 inhibitor. (M) The ROC curve of TMEscore predicting immunotherapeutic response for patients treated with PD1 inhibitor. (N) The correlation plot of TMEscore with integrated immune response score in TCGA GIAC cohort.